Abstract Library
Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.
Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.
ENETS Abstract Search
#3842 Long response to 177-Lu DOTATATE of a long malignant metastatic pheochromocytoma survivor
Introduction: A 64-year-old man was admitted on November 2010 with a CT-scan showing a 9cm right adrenal mass and high 24-hour urine metanephrins and cathecolamins. The mass was resected in December 2010 confirming a pT3N1 pheochromocytoma (PHEO). In May 2013 he presented a local recurrence that was resected proving metastatic lymphatic tissue. On May 2014 biochemical progression preceded a CT scan showing retroperitoneal lymphadenophaties with MIBG uptake. He was then treated with 131I-MIBG (two cycles) until May 2015, having biochemical and radiological response. After lymphatic tumor progression in January 2018, he received two more cycles of 131I-MIBG therapy (cumulative dose 800mCi) with proven refractory disease. He continued follow-up until two new abdominal masses appeared in October 2020. A high uptake in the 99Tc octreotide scintigraphy showed somatostatin receptors expression. The patient refused to participate in a clinical trial, so he was treated off-label with 177Lu-DOTATATE (800mCi) four doses from February to July 2021 achieving a near-complete response.
Conference:
Presenting Author: Martin Fernandez de Soignie A
Authors: Martin Fernandez de Soignie A, Martinez Moreno E, Antón-Pascual B, Pantin Gonzalez C, Sanchez Baños N,
Keywords: pheochromocytoma, 177-Lutetium,
Introduction: Chromogranin A (CgA) is a non-specific marker of neuroendocrine tumors (NET) and its significantly increased level is an unfavorable prognostic factor while the decrease in CgA during biotherapy with somatostatin analogs (SSA) correlates with the increase in profession free survival (PFS).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Sygula A, Jurecka-Lubieniecka B, Hasse-Lazar K, Michalik B, Ledwon A,
Introduction: For patients with nonfunctioning pNET ≥20 mm in size without distant metastasis, complete surgical resection is recommended as the primary curative strategy. Effective follow‐up programs are designed to detect recurrence at an early stage, given that treatment of limited disease has the most favorable outcome. However, data on post‐curative surgical recurrence remains limited, making it challenging to determine the best follow‐up strategy and to detect the best treatment options as an adjuvant therapy for selected patients.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Mastrangelo L
Authors: Mastrangelo L, Cipressi C, Masetti M, Zanello M, Romboli A,
Keywords: nomogram, pancreatic neuroendocrine tumor, recurrence,
Introduction: Surufatinib is a targeted inhibitor of tyrosine kinases VEGFR1, 2, & 3, FGFR1, and CSF-1R. The safety profile was favorable in 2 completed studies (NCT02133157, NCT02267967) conducted in China. A recent phase 3 placebo controlled study (NCT02588170) confirmed safety, and demonstrated superior efficacy (PFS: 9.2 v 3.8 months) of Surufatinib in Chinese pts with advanced extra-pancreatic NETs (epNET).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Dasari A, Paulson S, Sung M, Tucci C, Kauh J,
Keywords: Neuroendocrine Tumors, Pancreatic, Surufatinib,
#2166 A Family Bronchial Carcinoid Tumor.
Introduction: Typical and atypical bronchial carcinoids are neuroendocrine tumors of the lung. Family lung carcinoid tumors are rare and have been described as very rarely in literature.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Wassila O
Authors: Ougdi W, Bezzar-Ghomari S,
Keywords: atypical carcinoid, neuroendocrin, tumor, lung, family case.,